Gastric neuroendocrine tumor Medical Services in China

Gastric neuroendocrine tumors (gNETs) are rare, slow-growing neoplasms arising from enterochromaffin-like (ECL) cells or other neuroendocrine cells in the gastric mucosa. Classified under gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), gNETs are histologically and clinically heterogeneous, with three main types: Type 1 (associated with chronic atrophic gastritis and hypergastrinemia, most common and least aggressive), Type 2 (linked to Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1, rare), and Type 3 (sporadic, gastrin-independent, more aggressive with higher metastatic potential). Pathogenesis involves dysregulated gastrin signaling—particularly in Types 1 and 2—leading to ECL cell hyperplasia, dysplasia, and eventual tumorigenesis; Type 3 arises de novo via somatic mutations (e.g., in DAXX, ATRX, MEN1, or mTOR pathway genes) without hormonal driver involvement. Epidemiologically, gNETs account for <1% of all gastric malignancies and ~2–6% of all gastrointestinal NETs. Incidence is rising globally, likely due to increased endoscopic detection and improved histopathological classification; age-adjusted incidence in high-income countries ranges from 0.2 to 0.6 per 100,000 person-years, with peak diagnosis in the sixth to seventh decades. Risk factors include chronic autoimmune atrophic gastritis (especially with pernicious anemia), long-standing proton pump inhibitor use (controversial but biologically plausible due to induced hypergastrinemia), familial syndromes (MEN1, VHL), and H. pylori eradication in predisposed individuals. Unlike many gastrointestinal cancers, gNETs often present asymptomatically—detected incidentally during endoscopy for dyspepsia or anemia—or with nonspecific symptoms such as epigastric discomfort, nausea, early satiety, or iron-deficiency anemia secondary to chronic mucosal bleeding. Hormonally functional tumors are exceedingly rare in the stomach and seldom cause carcinoid syndrome. Quality of life impact is multifaceted: while low-grade gNETs (especially Type 1) carry excellent 5-year survival (>95%), patients face lifelong surveillance (annual or biennial upper endoscopy with targeted biopsies), anxiety around progression risk, dietary adjustments, and potential complications from repeated endoscopic resections (e.g., stricture, bleeding). Higher-grade or metastatic disease necessitates systemic therapies (somatostatin analogs, peptide receptor radionuclide therapy, everolimus, or chemotherapy), which may cause fatigue, diarrhea, hyperglycemia, or myelosuppression—further affecting daily functioning, work capacity, and psychosocial well-being. Early diagnosis, accurate grading (Ki-67 index and mitotic count per WHO 2022 classification), and multidisciplinary management—including gastroenterology, pathology, nuclear medicine, and oncology—are critical to optimizing outcomes and preserving quality of life.

Gastric neuroendocrine tumors (gNETs) are rare, heterogeneous neoplasms arising from enterochromaffin-like (ECL) cells or other neuroendocrine cell lineages within the gastric mucosa. They constitute approximately 1–2% of all gastrointestinal neuroendocrine tumors and are classified into three main types based on etiology, clinical behavior, and prognosis: Type 1 (associated with chronic atrophic gastritis and hypergastrinemia), Type 2 (associated with Zollinger–Ellison syndrome and multiple endocrine neoplasia type 1 [MEN1]), and Type 3 (sporadic, gastrin-independent, and typically more aggressive). The primary pathogenic driver across most gNETs is chronic hypergastrinemia, which acts as a potent trophic stimulus for ECL-cell proliferation. In Type 1 gNETs—accounting for ~70–80% of cases—chronic autoimmune atrophic gastritis leads to parietal cell loss, achlorhydria, and compensatory hypergastrinemia. Sustained gastrin elevation over years induces ECL-cell hyperplasia, dysplasia, and eventual neoplastic transformation. Type 2 gNETs arise in the context of gastrin-secreting duodenal or pancreatic gastrinomas (often MEN1-associated), resulting in markedly elevated serum gastrin levels and multifocal gastric NET development. In contrast, Type 3 gNETs lack evidence of hypergastrinemia or underlying gastric pathology; their oncogenesis involves somatic mutations in genes regulating cell cycle control (e.g., CDKN1B, TP53, DAXX/ATRX), chromatin remodeling, and PI3K/AKT/mTOR signaling, with frequent genomic instability and higher metastatic potential. Genetic factors play a pivotal role in subsets: germline mutations in MEN1 (encoding menin, a tumor suppressor) confer high lifetime risk for Type 2 gNETs, as well as parathyroid adenomas and pituitary tumors. Rarely, germline variants in CDKN1B (p27), AIP, or PRKAR1A may predispose to NETs, though gastric involvement is less common. Familial cases outside MEN1 remain exceedingly rare and poorly characterized. Environmental and modifiable risk factors are less definitively established Helicobacter pylori infection, particularly in the setting of pangastritis progressing to atrophic gastritis—a key antecedent to Type 1 gNETs. H. pylori eradication early in disease may mitigate progression, though its impact on established ECL hyperplasia is uncertain. Chronic use of proton pump inhibitors (PPIs) is associated with reversible hypergastrinemia and ECL-cell hyperplasia; however, large-scale epidemiologic studies have not demonstrated a causal link between PPI use and gNET development in patients without preexisting atrophic gastritis. Nevertheless, prolonged high-dose PPI therapy in individuals with undiagnosed atrophic gastritis may theoretically accelerate neoplastic progression. Other potential contributors include dietary factors such as high-salt, smoked, or nitrate-rich diets—known to exacerbate gastric mucosal injury and promote carcinogenesis in gastric adenocarcinoma—but direct evidence linking these to gNETs is lacking. Smoking is associated with increased risk of gastric adenocarcinoma and may modestly elevate gNET incidence through chronic inflammation and oxidative stress, though data are limited. Alcohol consumption has not been consistently implicated. Age is a significant non-modifiable risk factor: median diagnosis occurs in the sixth to seventh decade, reflecting the indolent, time-dependent nature of ECL-cell transformation. Female sex predominates in Type 1 gNETs (F:M ≈ 3:1), likely reflecting higher prevalence of autoimmune gastritis in women. Conversely, Type 3 gNETs show male predominance and occur at a slightly younger age. Importantly, gNETs are not linked to obesity, metabolic syndrome, or gastroesophageal reflux disease—unlike many other upper GI malignancies. Surveillance strategies emphasize endoscopic monitoring in high-risk cohorts (e.g., patients with confirmed atrophic gastritis, pernicious anemia, or MEN1), given the stepwise progression from chronic inflammation → atrophy → hypergastrinemia → ECL hyperplasia → dysplasia → NET. Early detection remains critical, as localized Type 1 and 2 gNETs (<1 cm, no invasion beyond lamina propria) carry excellent 5-year survival (>95%), whereas Type 3 tumors ≥2 cm or with deep submucosal invasion portend significantly worse outcomes. Understanding the interplay among autoimmune, infectious, genetic, and iatrogenic factors is essential for risk stratification, surveillance optimization, and personalized management in gastroenterology practice.

Gastric neuroendocrine tumors (gNETs) are rare, heterogeneous neoplasms arising from enterochromaffin-like (ECL) cells or other neuroendocrine cell lineages within the gastric mucosa. They account for approximately 1–2% of all gastrointestinal neuroendocrine tumors and are classified into three main types according to the European Neuroendocrine Tumor Society (ENETS) and WHO 2019 classification: Type 1 (associated with chronic atrophic gastritis and hypergastrinemia, typically sporadic and indolent), Type 2 (associated with Zollinger–Ellison syndrome and multiple endocrine neoplasia type 1 [MEN1], gastrin-driven but less common), and Type 3 (sporadic, non-gastrin-dependent, biologically aggressive, often larger and metastatic at diagnosis). Clinical presentation varies significantly by tumor type, size, functional status, and stage.

Early symptoms of gNETs are frequently absent or nonspecific, contributing to delayed diagnosis. In Type 1 and Type 2 gNETs, patients may remain asymptomatic for years, with lesions incidentally detected during upper endoscopy performed for unrelated dyspeptic complaints. When present, early manifestations often reflect underlying chronic gastritis rather than the tumor itself—e.g., mild epigastric discomfort, intermittent bloating, or subtle postprandial fullness. Small (<1 cm) Type 1 gNETs rarely cause hormonal syndromes; thus, biochemical markers such as chromogranin A (CgA) may be elevated due to achlorhydria-induced hypergastrinemia, not tumor burden. In contrast, early Type 3 gNETs may produce vague abdominal pain or unexplained iron-deficiency anemia secondary to occult mucosal bleeding—often overlooked without targeted investigation.

Typical symptoms emerge as tumors enlarge (>2 cm) or acquire invasive features. Epigastric or upper abdominal pain—often dull, persistent, and poorly localized—is the most common symptomatic presentation. Gastrointestinal bleeding manifests as melena, hematemesis, or iron-deficiency anemia in up to 30% of cases, particularly with exophytic or ulcerated lesions. Obstructive symptoms—including nausea, vomiting, early satiety, and postprandial distension—may occur with proximal gastric or fundal tumors causing luminal narrowing or pyloric involvement. Weight loss (unintentional, >5% body weight over 6 months) is a red-flag symptom strongly associated with Type 3 gNETs and advanced disease. Dysphagia is uncommon but may arise with cardia- or fundus-localized tumors extending into the gastroesophageal junction.

Accompanying symptoms depend on tumor functionality and secretory profile. While the majority of gNETs are nonfunctional (i.e., do not secrete bioactive peptides in clinically relevant amounts), a subset—particularly Type 2 and some Type 3 tumors—may co-secrete histamine, serotonin, gastrin, or pancreatic polypeptide. Gastrin hypersecretion (in Type 2) drives severe peptic ulcer disease, gastroesophageal reflux, and diarrhea—distinct from typical GERD due to refractoriness to standard proton-pump inhibitor (PPI) monotherapy. Histamine excess may contribute to flushing, pruritus, or gastric hypersecretion. Rarely, serotonin secretion leads to carcinoid syndrome (flushing, diarrhea, bronchospasm, right-sided valvular heart disease); however, this is exceedingly uncommon in gastric primaries due to hepatic first-pass metabolism—its presence strongly suggests liver metastases. Other systemic features include fatigue, anorexia, and night sweats, especially in metastatic or high-grade disease.

Complications arise from local invasion, metastasis, or endocrine effects. Local complications include gastric outlet obstruction, perforation (especially in ulcerated tumors), and chronic blood loss leading to symptomatic anemia requiring transfusion. Metastatic spread occurs most commonly to regional lymph nodes (perigastric, celiac, and para-aortic), liver (hematogenous), and bone. Hepatic metastases may precipitate carcinoid crisis (hypotension, tachycardia, bronchospasm, confusion) triggered by anesthesia, surgery, or chemotherapy. High-grade (G3) gNETs—particularly those with neuroendocrine carcinoma morphology—carry high risks of rapid progression, peritoneal carcinomatosis, and paraneoplastic syndromes including Cushing’s syndrome (ACTH secretion) or inappropriate ADH secretion (SIADH). Spontaneous tumor rupture is rare but life-threatening.

Diagnosis relies on multimodal integration. Upper gastrointestinal endoscopy remains the cornerstone: gNETs typically appear as small, submucosal, yellowish-white, well-circumscribed nodules—often multiple in Type 1/2, solitary in Type 3. Endoscopic ultrasound (EUS) is critical for assessing depth of invasion (T-stage), evaluating lymph node involvement (N-stage), and guiding fine-needle aspiration (FNA) or biopsy. Histopathological confirmation requires immunohistochemistry: positive staining for synaptophysin, chromogranin A, and CD56 confirms neuroendocrine differentiation; Ki-67 index and mitotic count determine grade (G1: Ki-67 ≤2%, mitoses <2/10 HPF; G2: Ki-67 3–20%, mitoses 2–20/10 HPF; G3: Ki-67 >20%, mitoses >20/10 HPF). Serum gastrin, CgA, and pancreatic polypeptide levels aid subclassification and monitoring. Cross-sectional imaging—contrast-enhanced CT or MRI abdomen/pelvis—evaluates locoregional extent and distant metastases. For functional or metastatic disease, somatostatin receptor imaging (e.g., 68Ga-DOTATATE PET/CT) demonstrates superior sensitivity and specificity over conventional imaging and guides peptide receptor radionuclide therapy (PRRT) eligibility.

Differential diagnosis must exclude mimics both endoscopically and histologically. Benign gastric polyps (hyperplastic, fundic gland) are common incidental findings but lack neuroendocrine immunoreactivity and exhibit no architectural complexity. Gastric adenocarcinoma may mimic ulcerated gNETs endoscopically but shows glandular differentiation, nuclear pleomorphism, and negative neuroendocrine markers. Gastrointestinal stromal tumors (GISTs) present as submucosal masses but stain positively for CD117 (c-KIT) and DOG1, not neuroendocrine markers. Carcinoid tumors of duodenal or ileal origin may metastasize to stomach but retain primary site phenotypic features (e.g., duodenal NETs often express PDX1 and NESP1). Lymphoma (especially MALT lymphoma) may arise in the setting of chronic gastritis and overlap endoscopically; however, it demonstrates B-cell immunophenotype (CD20+, CD79a+) and lacks neuroendocrine markers. Finally, metastatic neuroendocrine carcinoma from lung, pancreas, or breast must be excluded via clinical history, imaging, and comparative immunoprofiling (e.g., TTF-1 for lung, ISL1 for pancreatic origin). Accurate classification directly informs prognosis and management—Type 1 gNETs have 5-year survival >95%, whereas Type 3 G3 tumors approach <30%.

Gastric neuroendocrine tumors (gNETs) are rare, heterogeneous neoplasms arising from enterochromaffin-like (ECL) cells or other neuroendocrine cell lineages in the gastric mucosa. Classified primarily by the World Health Organization (WHO) into grades G1 (low-grade), G2 (intermediate-grade), and G3 (high-grade), and further stratified by etiology—most commonly type 1 (associated with chronic atrophic gastritis and hypergastrinemia), type 2 (Zollinger–Ellison syndrome with multiple endocrine neoplasia type 1), and type 3 (sporadic, gastrin-independent)—management must be individualized based on tumor size, grade, number, depth of invasion, lymph node involvement, and metastatic status. Treatment is coordinated within gastroenterology (digestive medicine) departments, often in multidisciplinary tumor boards involving endoscopists, surgical oncologists, nuclear medicine specialists, and medical oncologists.

Conservative management is appropriate for small, low-grade (G1/G2), non-invasive lesions (<1 cm), particularly in type 1 gNETs without evidence of deep submucosal invasion or lymphovascular infiltration. Endoscopic surveillance every 6–12 months with high-definition white-light and chromoendoscopy (e.g., indigo carmine) is standard. Serial serum chromogranin A (CgA), gastrin, and fasting gastric pH measurements help monitor disease activity and underlying hypergastrinemic drivers. In type 1 gNETs, long-term proton pump inhibitor (PPI) therapy—though necessary for symptom control in atrophic gastritis—is carefully evaluated, as prolonged hypergastrinemia may theoretically promote ECL-cell proliferation; however, current evidence does not support PPI discontinuation solely for tumor prevention in stable cases. Instead, optimization of gastric acid suppression while minimizing unnecessary dose escalation is advised. Lifestyle modifications—including smoking cessation, alcohol abstinence, and avoidance of chronic NSAID use—are recommended to reduce mucosal injury and inflammation.

Pharmacologic intervention centers on controlling hormonal syndromes and inhibiting tumor growth. Somatostatin analogues (SSAs), such as octreotide LAR (long-acting release) or lanreotide Autogel, are first-line for symptomatic hormone-secreting gNETs (e.g., carcinoid syndrome) and demonstrate antiproliferative effects in well-differentiated G1/G2 tumors, particularly those expressing somatostatin receptor subtype 2 (SSTR2), confirmed via 68Ga-DOTATATE PET/CT. Everolimus, an mTOR inhibitor, is indicated for progressive, advanced G1/G2 gNETs refractory to SSAs. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is reserved for SSTR-positive, metastatic, progressive disease after SSA failure and is increasingly available in tertiary centers across China. Chemotherapy (e.g., capecitabine plus temozolomide) is considered for high-grade (G3) gNETs with poor differentiation or rapidly progressive disease, though response rates remain modest. Targeted agents like sunitinib have limited data in gastric-specific NETs and are not routinely recommended outside clinical trials.

Surgical treatment remains definitive for localized, higher-risk gNETs. Endoscopic resection (ER) — including endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) — is curative for lesions ≤2 cm confined to the mucosa or superficial submucosa (sm1), with en bloc resection and negative margins confirmed histologically. ESD offers superior R0 resection rates (>95%) compared to EMR for larger or fibrotic lesions and is widely performed in Chinese digestive medicine centers with high technical proficiency. For tumors ≥2 cm, deeply invasive (sm2/sm3), multifocal, or with lymphovascular invasion, laparoscopic or open gastrectomy—ranging from wedge resection to distal or total gastrectomy with D1+/D2 lymphadenectomy—is indicated. Radical surgery is mandatory for type 3 gNETs regardless of size due to their aggressive biology. In metastatic settings, cytoreductive surgery may be considered if >90% tumor burden can be safely resected and functional status permits.

China offers distinct advantages in gNET management. First, endoscopic expertise is exceptionally advanced: over 300 certified ESD training centers exist nationwide, with standardized protocols endorsed by the Chinese Society of Gastrointestinal Endoscopy (CSGE). Second, integrated diagnostics—including rapid turnaround 68Ga-DOTATATE PET/CT, next-generation sequencing for molecular profiling (e.g., MEN1, DAXX/ATRX), and centralized pathology review through national reference networks—enhance diagnostic accuracy. Third, cost-effective access to biosimilar SSAs and domestically manufactured PRRT isotopes (e.g., 177Lu-labeled peptides produced under NMPA approval) improves treatment affordability and timeliness. Fourth, large-scale prospective registries (e.g., the China Neuroendocrine Tumor Registry, CNTR) facilitate real-world evidence generation and protocol refinement. Finally, seamless coordination between tertiary hospitals and community health centers enables longitudinal follow-up with standardized electronic health records and AI-assisted lesion tracking during surveillance endoscopy.

Post-treatment recovery emphasizes structured, evidence-based monitoring and holistic support. Patients undergoing ER require 4–6 weeks of soft diet, avoidance of anticoagulants/NSAIDs, and repeat endoscopy at 3 months to confirm complete resection and assess for recurrence. After gastrectomy, nutritional rehabilitation with dietitian-led counseling—focusing on small, frequent meals rich in protein and vitamin B12 supplementation—is critical. All patients should undergo lifelong surveillance: CgA and gastrin every 3–6 months, abdominal MRI or CT every 6–12 months, and 68Ga-DOTATATE PET/CT annually for high-risk or metastatic cases. Psychosocial support—including access to oncology social workers and peer support groups—is integral, given the chronic, unpredictable nature of NETs. Patients are counseled to recognize red-flag symptoms (e.g., new-onset flushing/diarrhea, unexplained weight loss, gastrointestinal bleeding) and seek prompt evaluation. Finally, participation in clinical trials—particularly those evaluating novel radiopharmaceuticals, immunotherapies, or combination regimens—is actively encouraged, with over 40 active gNET-focused trials registered in China’s Clinical Trial Registry (ChiCTR).